Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia

摘要: The current interest in epigenetic priming is underpinned by the belief that remodelling of landscape will sensitise tumours to subsequent therapy. In this pre-clinical study, paediatric AML cells expanded culture and primary xenografts were treated with decitabine, a DNA demethylating agent, cytarabine, frontline cytotoxic agent used treatment AML, either alone or combination. Sequential decitabine cytarabine was found be more effective reducing tumour burden than suggesting sequential delivery these agents may have real clinical advantage AML. However we no evidence suggest outcome dependent on hypomethylating as benefits observed independent order which drugs administered.